A Phase 3 clinical trial of an antibody drug that enrolled residents and staff at skilled nursing and assisted living facilities found that the treatment significantly reduced the risk of contracting symptomatic COVID-19. The antibody drug, bamlanivimab (LY-CoV555), was developed by pharmaceutical giant Eli Lilly and Company (NYSE: LLY) for clinical use with the Vancouver-based […]